CAR T-cells
A human CD34 hinge region that allows detection as well as rapid CliniMACS-mediated enrichment of successfully engineered CAR-T cells.
Rapid and easy staining for follow-up of CARs
Rapid and easy isolation of successfully engineered CAR T cells
Not susceptible to Fcg‑receptor binding
Modular composition enables other modifications in the hinge region
therapeutic development
For a large number of constructs, the hinge region consists of the CH2CH3 domain of a human IgG antibody, which can bindsto Fcg-receptors on macrophages and other cells thereby resulting in cross-activation and activation-induced cell death in vivo independent of recognition of the target antigen. The researchers in this invention haved replaced the CH2CH3 site by fragments of the human CD34 antigen that contain the epitope for the CD34 antibody QBEND10 that is used in the CliniMACS device sold by Miltenyi Biotech GmbH.
Licensing
08/09/2016 00:00:00
EP20160187740 20160908
- international:
C07K14/705; C07K14/725
- cooperative:
A61P35/02; C07K14/7051; C07K14/70517; C07K14/70521; C07K14/70535; C07K14/70578; C07K14/70596; C07K16/2878; C07K16/2896; C07K2317/53; C07K2317/622; C07K2319/00; C07K2319/02; C07K2319/03
Patent application
4813
德國
